Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 176   

Articles published

PFE 30.45 +0.01 (0.03%)
price chart
Why Pfizer Inc. (PFE) May Not Bid For AstraZeneca plc (ADR) (AZN) Again?
If investors thought Pfizer Inc. (NYSE:PFE) would still pursue AstraZeneca plc (ADR) (NYSE:AZN) deal then their hopes are up in the air.
Merck Collaboration Rules Out AstraZeneca Acquisition--For Now  Seeking Alpha
Healthcare Stocks in the Spotlight - Pfizer Inc. (NYSE:PFE), DaVita ...  Techsonian (press release)
Related articles »  
Pfizer, Germany's Merck to Develop Tumor Treatment
FRANKFURT� Pfizer Inc. and Germany's Merck KGaA are teaming up to develop a new tumor treatment product in an effort to boost their respective oncology businesses, even as U.S.
Pfizer Cancer Pact With Merck Shows Waning Astra Pursuit  Bloomberg
Pfizer, Germany''s Merck to Develop Tumor Treatment -- Update  Nasdaq
Related articles »  
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether.
Related articles »  
Op-Ed: Pfizer Inc. is active, vital, taxpaying part of Eastern Connecticut
The Chamber of Commerce of Eastern Connecticut would like to set the record straight regarding Pfizer Inc.'s presence and future in southeastern Connecticut.
Related articles »  
Warren Buffett's Investing Strategy: Is Pfizer Inc. a Perfect Fit?
Yet, one company you won't currently find in Buffett and Berkshire's portfolio is the world's largest pharmaceutical company by revenue, Pfizer (NYSE: PFE ) . Today, we'll take a closer look at whether or not Pfizer would make a perfect fit for Warren ...
Related articles »  
Is Pfizer Spending Enough On R&D?
The company also stated in the 10-K that R&D spending may include upfront and milestone payments for intellectual property rights.
Related articles »  
Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic ...
LOS ANGELES, Nov. 18, 2014 /PRNewswire/ -- Sanguine Biosciences - a biotechnology company focusing on technology development, patient engagement and study recruitment - will use its proprietary mobile application and direct-to-patient platform, ...
Related articles »  
Pfizer Hasn't Ruled Out Potential Inversions, Chief Says
Pfizer Inc. hasn't ruled out pursuing a so-called �inversion� acquisition that would lower its tax bill, though the drug maker's CEO acknowledged Tuesday the U.S.
New Tax Rules Won't Stop Pfizer From Bidding U.S. Goodbye  Bloomberg
Pfizer CEO: Still exploring tax-inversion deal  Philly.com
Related articles »  
Pfizer to pay up to $2 billion for cancer alliance with Germany's Merck
Pfizer said it will pay Merck $850 million up front and other payments up to as much as $2 billion for the rights to jointly develop and commercialize an antibody that the German companty is currently working on.
Pfizer Inc. (PFE) Strikes $2.85 Billion Deal With Merck KGaA To Co-Develop ...
Previously, Pfizer had been looking to expand its immune-oncology portfolio and had approached London-based AstraZeneca plc (ADR) (NYSE:AZN) with a bid to take over the company. The US pharmaceutical giant extended a $116 billion offer to ...